RADX - Radiopharm Theranostics Limited News

Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of R

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBar

Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-ma

Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report)'s share price trade

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee t

Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tu

Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design

RAD101 is the Company's novel Fluorine-18-labeled small-molecule imaging agent that targets fatt

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday&#39

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market sess

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

US Stocks Mixed; American Express Shares Fall Following Q2 Results

US stocks mixed, Dow Jones up 0.2%. Real estate shares up 1.3%. American Express falls 6%. Ohmyhome,

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

Radiopharm Theranostics Announces $4.1M U.S. Direct Offering Of Shares And Warrants Along With A$12.

Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company&#34

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Add

NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Na

Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort O

Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage ob

Radiopharm Theranostics Announces Data From All Thirty Evaluable Patients In Its Phase 2B Trial Of R

14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sen

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD2

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the pa

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's p

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For T

Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranost

HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price T

HC Wainwright & Co. analyst Robert Burns initiates coverage on Radiopharm Theranostics (NASDA

Radiopharm Theranostics Issues Business Update

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

Radiopharm Theranostics Reports Business Update

Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent b

Radiopharm Theranostics Announces That New Data From The Ongoing Phase 0/1 Heat Trial Evaluating 177

Key Findings from the AACR Abstract and PosterMeaningful tumor uptake of 177Lu-RAD202 was observed a

Radiopharm Announces Dosing Of Final Patient In Phase 2b Imaging Trial Evaluating RAD 101 In Individ

The U.S. multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic pe

Radiopharm Theranostics Advances Cancer Drug Trial After Safety Review

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a cl

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.

Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor up

Radiopharm Theranostics Says First Patient Dosed In First-In-Human Phase 1 Clinical Trial Of RAD 402

On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual e

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostat

On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual

proactiveinvestors.com

Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase

proactiveinvestors.com

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF, NASDAQ:RADX) has dosed the first patient in a Phase

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics (NASDAQ: RADX) executives and clinical investigators highlighted new interim

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results

RAD 101 is Radiopharm's novel, small-molecule imaging agent targeting fatty acid synthase (FASN) and

Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results

Radiopharm Theranostics says Phase 2b interim data showing 90% MRI concordance for RAD 101, with fin

Radiopharm Drug Shows 90% Accuracy In Detecting Brain Tumors In Trial

Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage

Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:R

Radiopharm Theranostics (NASDAQ: RADX - Get Free Report) and Biodexa Pharmaceuticals (NASDAQ: BDRX -

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Broke

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been

Radiopharm Theranostics Doses First Participant In Phase 1/2 Clinical Study Of 177Lu-Betabart

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage b

Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months

Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled w

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Bro

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ: RADX - Get Free Report) have been

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate

Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and R

RAD Increases Ownership in Radiopharm Ventures to 87.5%

SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiophar

12 Health Care Stocks Moving In Monday's After-Market Session